139 related articles for article (PubMed ID: 26081451)
1. Urinary N telopeptide levels in predicting the anti-nociceptive responses of zoledronic acid and paclitaxel in a rat model of bone metastases.
Gui Q; Xu C; Li D; Zhuang L; Xia S; Yu S
Mol Med Rep; 2015 Sep; 12(3):4243-4249. PubMed ID: 26081451
[TBL] [Abstract][Full Text] [Related]
2. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid.
Lipton A; Cook R; Saad F; Major P; Garnero P; Terpos E; Brown JE; Coleman RE
Cancer; 2008 Jul; 113(1):193-201. PubMed ID: 18459173
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.
Lipton A; Cook RJ; Major P; Smith MR; Coleman RE
Oncologist; 2007 Sep; 12(9):1035-43. PubMed ID: 17914073
[TBL] [Abstract][Full Text] [Related]
4. N-Telopeptide of Type I Collagen Long-Term Dynamics in Breast Cancer Patients With Bone Metastases: Clinical Outcomes and Influence of Extraskeletal Metastases.
Ferreira AR; Alho I; Shan N; Matias M; Faria M; Casimiro S; Leitzel K; Ali S; Lipton A; Costa L
Oncologist; 2016 Dec; 21(12):1418-1426. PubMed ID: 27534575
[TBL] [Abstract][Full Text] [Related]
5. Prospective Evaluation of Zoledronic Acid in the Treatment of Bone Metastases from Differentiated Thyroid Carcinoma.
Orita Y; Sugitani I; Takao S; Toda K; Manabe J; Miyata S
Ann Surg Oncol; 2015 Nov; 22(12):4008-13. PubMed ID: 25762482
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of zoledronic acid combined with chemotherapy in treatment of skeletal metastases of non-small cell lung cancer and the bone metabolic markers].
Hu XY; Zou QF; Jin C; Li WD; Chen WS; Ma L
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jun; 30(6):1343-6. PubMed ID: 20584674
[TBL] [Abstract][Full Text] [Related]
7. Hypernociceptive responses following the intratibial inoculation of RM1 prostate cancer cells in mice.
Llorián-Salvador M; Pevida M; Fernández-García MT; Lastra A; Obaya A; Cal S; Hidalgo A; Menéndez L; Baamonde A
Prostate; 2015 Jan; 75(1):70-83. PubMed ID: 25263196
[TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.
Hirsh V; Major PP; Lipton A; Cook RJ; Langer CJ; Smith MR; Brown JE; Coleman RE
J Thorac Oncol; 2008 Mar; 3(3):228-36. PubMed ID: 18317064
[TBL] [Abstract][Full Text] [Related]
9. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
[TBL] [Abstract][Full Text] [Related]
10. [Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma].
Dong M; Feng FY; Zhang Y; Xie GR; Wang YJ; Liu JW; Song ST; Zhou QH; Ren J; Jiao SC; Li J; Wang XW; Chen Q; Wang ZH; Xu N; Feng JF
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):215-20. PubMed ID: 18756940
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of acid-sensing ion channel 3 within dorsal root ganglia in a rat model of bone cancer pain.
Qiu F; Wei X; Zhang S; Yuan W; Mi W
Neuroreport; 2014 Aug; 25(12):887-93. PubMed ID: 25006846
[TBL] [Abstract][Full Text] [Related]
12. Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain.
Walker K; Medhurst SJ; Kidd BL; Glatt M; Bowes M; Patel S; McNair K; Kesingland A; Green J; Chan O; Fox AJ; Urban LA
Pain; 2002 Dec; 100(3):219-229. PubMed ID: 12467993
[TBL] [Abstract][Full Text] [Related]
13. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.
Pectasides D; Nikolaou M; Farmakis D; Kanakis I; Gaglia A; Kountourakis P; Karamanos NK; Economopoulos T; Raptis SA
Anticancer Res; 2005; 25(2B):1457-63. PubMed ID: 15865105
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma.
Zhou Z; Guan H; Duan X; Kleinerman ES
Cancer; 2005 Oct; 104(8):1713-20. PubMed ID: 16121404
[TBL] [Abstract][Full Text] [Related]
15. Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial.
Broom RJ; Hinder V; Sharples K; Proctor J; Duffey S; Pollard S; Fong PC; Forgeson G; Harris DL; Jameson MB; O'Donnell A; North RT; Deva S; Hanning FJ; Grey A; Findlay MP
Clin Genitourin Cancer; 2015 Feb; 13(1):50-8. PubMed ID: 25163397
[TBL] [Abstract][Full Text] [Related]
16. Utility of urinary type I collagen cross-linked N-telopeptide as a prognostic indicator in breast cancer patients with bone metastases.
Shizuku M; Shibata M; Okumura M; Takeuchi D; Kikumori T; Mizuno Y
Breast Cancer; 2020 Nov; 27(6):1065-1071. PubMed ID: 32415556
[TBL] [Abstract][Full Text] [Related]
17. A Pilot Trial Evaluating Zoledronic Acid Induced Changes in [
Vaishampayan UN; Tehrani OS; Lawhorn-Crews JM; Heilbrun LK; Dobson K; Smith D; Dickow B; Shields AF
Mol Imaging Biol; 2017 Dec; 19(6):810-816. PubMed ID: 28289967
[TBL] [Abstract][Full Text] [Related]
18. Bone Pain Induced by Multiple Myeloma Is Reduced by Targeting V-ATPase and ASIC3.
Hiasa M; Okui T; Allette YM; Ripsch MS; Sun-Wada GH; Wakabayashi H; Roodman GD; White FA; Yoneda T
Cancer Res; 2017 Mar; 77(6):1283-1295. PubMed ID: 28254863
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
[TBL] [Abstract][Full Text] [Related]
20. Analgesic efficacy and mode of action of a selective small molecule angiotensin II type 2 receptor antagonist in a rat model of prostate cancer-induced bone pain.
Muralidharan A; Wyse BD; Smith MT
Pain Med; 2014 Jan; 15(1):93-110. PubMed ID: 24433468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
